Long Noncoding RNA SNHG12 Indicates the Prognosis and Accelerates Tumorigenesis of Diffuse Large B-Cell Lymphoma Through Sponging MicroR-195

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Jul 2

PMID 32606771

Citations 14

Authors

Li-Yan Chen

Xiao-Min Zhang

Bi-Qing Han

Hai-Bin Dai

Affiliations

Soon will be listed here.

Abstract

Background: Small nucleolar RNA host gene 12 (SNHG12) expression is associated with multiple cancers, including renal cell carcinoma, prostate cancer, cervical cancer, nasopharyngeal carcinoma, colorectal cancer, and hepatocellular carcinoma. However, SNHG12 biological function is unclear in diffuse large B-cell lymphoma (DLBCL).

Methods: SNHG12 expression and associated clinicopathological characteristics were evaluated in DLBCL tissues. CCK-8 and transwell assay were used to analyze the in vitro role of SNHG12 in DLBCL progression. The xenograft model was used to explore the in vivo role of SNHG12 in DLBCL growth. The physical interaction between SNHG12 and miR-195 was confirmed using bioinformatics analysis and a dual luciferase assay.

Results: SNHG12 expression was upregulated in DLBCL tissues and correlated with patients' prognosis. SNHG12 downregulation inhibited cell growth, migration, and invasion of DLBCL cells in vitro, while its overexpression promoted these cellular processes. Moreover, SNHG12 knockdown repressed tumorigenesis of DLBCL cells in vivo. Further experiments demonstrated that miR-195 is a target of SNHG12 in DLBCL and that their expression negatively correlates in DLBCL. SNHG12 functioned as a competing endogenous RNA for miR-195 in DLBCL cells and miR-195 upregulation abolished the effects of SNHG12 on of DLBCL progression.

Conclusion: SNHG12 predicts poor clinical outcome and serves as a novel oncogene in DLBCL via miR-195 sponging. We also suggest that SNHG12 can be used as a potential therapeutic candidate for DLBCL patients.

Citing Articles

Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.

Khanmohammadi S, Fallahtafti P J Cell Mol Med. 2023; 27(14):1928-1946.

PMID: 37246627 PMC: 10339099. DOI: 10.1111/jcmm.17795.

Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma.

Li M, Huang F, Xie Z, Hong H, Xu Q, Peng Z Cancer Med. 2023; 12(3):3812-3829.

PMID: 36812125 PMC: 9939161. DOI: 10.1002/cam4.5115.

Small but strong: Pivotal roles and potential applications of snoRNAs in hematopoietic malignancies.

Dong J, Wang H, Zhang Z, Yang L, Qian X, Qian W Front Oncol. 2022; 12:939465.

PMID: 36033520 PMC: 9413531. DOI: 10.3389/fonc.2022.939465.

LncRNA promotes the malignant progression of melanoma by targeting .

Xie Y, Chen G Ann Transl Med. 2022; 10(4):226.

PMID: 35280401 PMC: 8908113. DOI: 10.21037/atm-22-214.

The emerging role non-coding RNAs in B cell-related disorders.

Ghafouri-Fard S, Khoshbakht T, Hussen B, Taheri M, Jamali E Cancer Cell Int. 2022; 22(1):91.

PMID: 35193592 PMC: 8862212. DOI: 10.1186/s12935-022-02521-1.

References

Wang N, Cao Y, Ge X, Nie J, Yu Y, Li Q . MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis. Cancer Manag Res. 2019; 11:7967-7979. PMC: 6709821. DOI: 10.2147/CMAR.S205841. View

Wang J, Xu C, Wu H, Shen S . LncRNA SNHG12 promotes cell growth and inhibits cell apoptosis in colorectal cancer cells. Braz J Med Biol Res. 2017; 50(3):e6079. PMC: 5333723. DOI: 10.1590/1414-431X20176079. View

Smedby K, Hjalgrim H . Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011; 21(5):293-8. DOI: 10.1016/j.semcancer.2011.09.010. View

Jiang W, Huang H . [The evolution and curative effect of diffuse large B cell lymphoma treatment in China]. Zhonghua Xue Ye Xue Za Zhi. 2014; 35(4):357-60. DOI: 10.3760/cma.j.issn.0253-2727.2014.04.025. View

Yu S, Jing L, Yin X, Wang M, Chen Y, Guo Y . MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017; 8(59):99757-99771. PMC: 5725129. DOI: 10.18632/oncotarget.20909. View

Lan T, Ma W, Hong Z, Wu L, Chen X, Yuan Y . Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. J Exp Clin Cancer Res. 2017; 36(1):11. PMC: 5223416. DOI: 10.1186/s13046-016-0486-9. View

Wu Z, Chen D, Wang K, Cao C, Xu X . Long Non-coding RNA SNHG12 Functions as a Competing Endogenous RNA to Regulate MDM4 Expression by Sponging miR-129-5p in Clear Cell Renal Cell Carcinoma. Front Oncol. 2019; 9:1260. PMC: 6882951. DOI: 10.3389/fonc.2019.01260. View

Flavin R, Smyth P, Laios A, OToole S, Barrett C, Finn S . Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol. 2008; 22(2):197-205. DOI: 10.1038/modpathol.2008.135. View

Bhan A, Soleimani M, Mandal S . Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965-3981. PMC: 8330958. DOI: 10.1158/0008-5472.CAN-16-2634. View

10.

Qu L, Ding J, Chen C, Wu Z, Liu B, Gao Y . Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell. 2016; 29(5):653-668. DOI: 10.1016/j.ccell.2016.03.004. View

11.

Jarroux J, Morillon A, Pinskaya M . History, Discovery, and Classification of lncRNAs. Adv Exp Med Biol. 2017; 1008:1-46. DOI: 10.1007/978-981-10-5203-3_1. View

12.

Jin X, Chen X, Zhang Z, Hu W, Ou R, Li S . Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b/STAT3 axis. J Cell Physiol. 2018; 234(5):6624-6632. DOI: 10.1002/jcp.27403. View

13.

Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L . miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells. PLoS One. 2015; 10(12):e0144073. PMC: 4674136. DOI: 10.1371/journal.pone.0144073. View

14.

Deng J, Wang W, Yu G, Ma X . MicroRNA‑195 inhibits epithelial‑mesenchymal transition by targeting G protein‑coupled estrogen receptor 1 in endometrial carcinoma. Mol Med Rep. 2019; 20(5):4023-4032. PMC: 6797983. DOI: 10.3892/mmr.2019.10652. View

15.

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8(6):e1000412. PMC: 2893951. DOI: 10.1371/journal.pbio.1000412. View

16.

Wu X, Xia T, Cao M, Zhang P, Shi G, Chen L . LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Technol Cancer Res Treat. 2019; 18:1533033819887962. PMC: 6880033. DOI: 10.1177/1533033819887962. View

17.

Zhou S, Yu L, Xiong M, Dai G . LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p. Biochem Biophys Res Commun. 2017; 495(2):1822-1832. DOI: 10.1016/j.bbrc.2017.12.047. View

18.

Luminari S . Bridging the gap between epidemiology and clinical research in lymphoma. Leuk Lymphoma. 2013; 54(9):1855-6. DOI: 10.3109/10428194.2013.777838. View

19.

Lu S, Sun Z, Tang L, Chen L . LINC00355 Promotes Tumor Progression in HNSCC by Hindering MicroRNA-195-Mediated Suppression of HOXA10 Expression. Mol Ther Nucleic Acids. 2019; 19:61-71. PMC: 6920228. DOI: 10.1016/j.omtn.2019.11.002. View

20.

Wang P, Chen D, Ma H, Li Y . LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017; 8(48):84086-84101. PMC: 5663579. DOI: 10.18632/oncotarget.20475. View